Clinical trials: Post Stroke Upper Limb Spasticity
Stroke, Upper Limb Spasticity
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
The purpose of this study is to investigate if early administration (i.e. within 12 weeks after stroke) of Dysport® 500 U injections may delay the appearance or the progression of upper limb symptomatic spasticity.
- Trial name
- ONTIME Pilot (NCT02321436)
- Testing
- Botulinum toxin type A
- Where
- 4 sites in Malaysia, Philippines and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Post-stroke Arm Spasticity
Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation)
Botulinum toxin A (BoNT-A) is effective and safe in alleviating post-stroke spasticity and reducing the burden of associated symptoms.
- Trial name
- EARLYBIRD (NCT01840475)
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 302 people
- Sponsor
- Ipsen
Upper Limb Spasticity After Stroke
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
- Trial name
- DECIDE (NCT01239628)
- Where
- 11 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- Ipsen
Cerebrovascular Accident
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
This trial is a multicenter, double-blind, randomized, placebo-controlled study to compare GSK1358820 (Botulinum Toxin Type A, also known as "OnabotulinumtoxinA" or "Botox") with placebo on the efficacy and safety of treatment in…
- Trial name
- NCT01153815
- Testing
- GSK1358820(Botulinum toxin type A)
- Where
- 13 sites in China
- Volunteers
- 170 people
- Sponsor
- GlaxoSmithKline
Spasticity, Stroke
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Purpose: This study is a Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb(wrist, finger…
- Trial name
- NCT01945684
- Testing
- Botulinum toxin type A
- Where
- South Korea
- Volunteers
- 197 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Upper Limb Spasticity Post-Stroke
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke
This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal.
- Trial name
- P_Dysport_CS (NCT02384330)
- Where
- 3 sites in Portugal
- Volunteers
- 57 people
- Sponsor
- Ipsen
Spasticity, Post-Stroke
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
This trial is a multicenter, open-label study to evaluate the safety and efficacy of GSK1358820 for treatment in post-stroke subjects with focal wrist, finger and in some cases, thumb spasticity.
- Trial name
- NCT01205451
- Testing
- Botulinum toxin type A
- Where
- 13 sites in China
- Volunteers
- 109 people
- Sponsor
- GlaxoSmithKline
Cerebrovascular Accident
A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare Botulinum Toxin Type A for Injection (HengLi®) with placebo on the efficacy and safety of treatment in post-stroke subjects with focal…
- Trial name
- NCT02280083
- Testing
- Botulinum Toxin Type A for Injection
- Volunteers
- 180 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Post-stroke Upper Limb Spasticity
Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity
Multicenter, randomized, double-blind, active-controlled, parallel-design study to evaluate the safety and efficacy of CKDB-501A in Subjects with Post-stroke Upper Limb Spasticity
- Trial name
- NCT05382767
- Testing
- CKDB-501A, Botox®
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- CKD Bio Corporation
Spasticity
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine…
- Trial name
- ETREAT (NCT02275312)
- Where
- 17 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Ipsen
Post Stroke Upper Limb Spasticity
To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Investigational Product: LIZTOX inj 100unit(HU-014) Title : Multi Center, Phase III Clinical Trial to Evaluate the efficacy and Safety of LIZTOX Inj in the Treatment of Post Stroke Upper Limb Spasticity Sites and investigators …
- Trial name
- HU-014 (NCT05289921)
- Testing
- HU-014 Inj
- Where
- South Korea
- Volunteers
- 198 people
- Sponsor
- Huons Co., Ltd.
Stroke, Spasticity
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
The purpose of this study is to evaluate the safety and efficacy of Botulax® compared to Botox® reducing upper limb muscle tone in post stroke patients.
- Trial name
- NCT01915459
- Testing
- Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®)
- Where
- 6 sites in South Korea
- Volunteers
- 186 people
- Sponsor
- Hugel